Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.
Le, Hannah Ladino, Daniel Lowry, Chrissy Rifi, Nada Baijal, Shobhit
Le, Hannah
Ladino, Daniel
Lowry, Chrissy
Rifi, Nada
Baijal, Shobhit
Abstract
Introduction: This study aimed to estimate the NHS costs of managing patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small-cell lung cancer (aNSCLC), with and without brain metastases. Patients were treated with first-line (1 L) ALK tyrosine kinase inhibitors (TKIs).
Methods: We built an economic model to estimate the annual costs of managing ALK+ aNSCLC patients with and without brain metastases using estimated NHS health care resource use (HCRU) consumption. The ALK TKIs included in our model were lorlatinib, crizotinib, alectinib and brigatinib. We based our estimates on the cumulative incidence of brain metastases in four clinical trials - CROWN, ALEX, ALESIA and ALTA-1L.
Results: For the first year of treatment, our model estimated the annual cost of managing patients with brain metastases to be £14,870. Patients without brain metastases cost £4,133. The NHS HCRU cost savings generated by treating patients with lorlatinib increased significantly over time and were greater in patients without brain metastases at the start of their treatment (at baseline) with lorlatinib. This reflects the prevention of brain metastases with 1 L lorlatinib.
Conclusion: The longitudinal cost data demonstrate that lorlatinib leads to potentially lower NHS management costs of brain metastases in patients with ALK+ aNSCLC.
MIDER Authors
Affiliations
Date
2026-07-21
Type
Article
Collections
Citation
Le H, Ladino D, Lowry C, Rifi N, Baijal S. Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK. Lung Cancer Manag. 2026 Dec;15(1):2696220. doi: 10.1080/17581966.2026.2696220.